Antibiotic chemotherapy effectively cures many infections caused by susceptible bacterial pathogens. However, in some cases, even extended treatment duration does not completely eradicate the pathogenic bacteria from host tissues. A common model for underlying mechanisms assumes the stochastic formation of bacterial persisters similar to observations in laboratory cultures. However, alternative explanations related to the complexity of infected host tissues could also be relevant. We discuss several of these aspects and emphasize the need for integrated analysis as a basis for new control strategies.
Corresponding author:
Dirk Bumann
Competing interests:
No competing interests were disclosed.
Grant information:
This work was supported by Swiss National Foundation grants 310030_156818 and 310030_18231
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Antibiotics have been saving the lives of millions of people. For most bacterial pathogens, short-term treatments of a few days effectively cure infections and prevent relapses1,2. However, in some cases such as tuberculosis and other chronic infections such as deep-seated abscesses with Staphylococcus aureus, severe typhoid fever, or polymicrobial infections of patients with cystic fibrosis, extended treatments over months and even years can fail to completely eradicate the pathogens from tissues, posing a risk for relapse (Figure 1A). Many treatment failures are due to inheritable antibiotic resistance. However, surprisingly, treatment failures also occur when the pathogen retains full susceptibility to the antibiotics of choice in laboratory tests. There is an urgent medical need to improve the efficacy and shorten the treatments for these patients on the basis of a detailed mechanistic understanding of the problem. Several different factors influence antibiotic activities against pathogenic bacteria in host tissues. Most research groups active in the field focus on one particular factor: the stochastic variation of pathogen cells. However, other factors could be at least as important. In this review, we discuss some of these aspects and stress the need for an integrated analysis (Figure 1B).
Figure 1. Treatment failures and potential causes.
(A) Incomplete eradication of bacterial pathogens during extended antimicrobial chemotherapy causes a risk for relapses after termination of therapy. (B) Possible mechanisms that enable a bacterial subset (red) to survive during treatment while the rest of the bacterial population (blue) is successfully eradicated.
Stochastic variation of bacterial properties in laboratory cultures
Bacterial cultures show heterogeneous properties even under completely homogeneous laboratory conditions indicating important endogenous stochastic variation within bacterial cells3–5. Exposure of bacterial cultures to lethal concentrations of bactericidal antibiotics rapidly kills most bacterial cells, but a small fraction of cells can survive for extended periods. It is possible that similar processes occur also in infected host tissues where they could contribute to incomplete eradication under antimicrobial chemotherapy. Because this phenomenon is readily observable in vitro, it has attracted the attention of a large number of research groups.
In many cases, the surviving small subset of bacteria represents non-growing remnant cells of a previous stationary culture that have an extended lag phase6. Such persisters are thus one particular instance of the widely characterized extensive heterogeneity of stationary-phase cultures7. A variety of other stress conditions also lead to increased antibiotic tolerance, including low ATP levels8, over-expression of toxins or unrelated proteins9, translation arrest10,11, oxidative stress12, and pre-exposure of cells to sub-MIC levels of bactericidal antibiotics13. Importantly, even growing bacteria show widely heterogeneous kill rates indicating that dormancy is not absolutely required for survival during antibiotic exposure14–17, implying alternative mechanisms leading to heterogeneous killing rates in clonal populations. These include asymmetric cell division4,18,19 with uneven partitioning of efflux pumps among daughter cells20, heterogeneous expression of prodrug-activating enzymes14, transient gene amplifications21, and heterogeneous induction of specific stress responses17.
Although endogenous stochastic variation in bacteria often is assumed to play a major role in impairing antibiotic efficacy, empirical evidence is surprisingly scarce in infected tissues22. Some clinical isolates of Pseudomonas aeruginosa and Escherichia coli from antibiotic-treated patients showed increased persister frequencies23,24, but this could also reflect fitness advantages of persisters under hostile host conditions or phage attacks. One argument against a general clinical relevance of persisters is the effectiveness of short-term antibiotic chemotherapy against many pathogens, which readily form refractory persisters in laboratory cultures1,2. Persisters thus might arise in patients but the host immune system seems to be capable of eradicating them quickly22. Moreover, bacteriostatic antibiotics, which cause population-wide growth arrest in bacteria and make them tolerant against other antibiotics, are as effective as bactericidal antibiotics for the treatment of most infectious diseases25. However, the distinction between bacteriostatic and bactericidal antibiotics is not absolute, as many “bacteriostatic” drugs can kill bacteria at higher exposure levels or during extended exposure times or both25. In addition, translation arrest by bacteriostatic antibiotics might impair survival in host tissues due to an inability to produce essential virulence factors or stress defenses. Finally, non-growing persisters can also occur in biofilms where they could escape clearance by host phagocytes26.
Although the general relevance of bacterial persisters in infectious diseases remains unclear27, they might be crucial for infections with frequent relapses even after extended treatment durations28,29. However, other much less studied mechanisms could also contribute to infection relapse.
Pathogen physiology in host tissues
Clinical microbiology relies largely on standard in vitro assays in rich media to assess antibiotic susceptibility of pathogens. The results often are predictive of therapeutic efficacy, but pathogen physiology is significantly different under assay conditions compared with infected host tissues30. Genetic screens in diverse pathogens typically have revealed many hundreds of virulence genes that are specifically required in host tissues but not in rich broth cultures, indicating large-scale relevant functional differences. Several parameters that differ between tissues and broth cultures also have a major impact on antibiotic activities. This includes31 oxygen tension32, carbon dioxide tension33,34, metabolite concentrations35, pH36,37, and antimicrobial effector molecules of the host immune system such as cationic antimicrobial peptides (CAMPs)38 and nitric oxide39. Limited nutrient supply and stress conditions can result in slow pathogen proliferation, which strongly affects the activity of most antibiotics40–42. Finally, pathogens can also adapt to the antibiotic exposure43 and this adaptation might be more successful when antibiotics gradually penetrate into the infection site, compared with abrupt exposure in standard in vitro assays. All of these effects might lead to poor antibiotic efficacy, requiring extended treatment times.
Pathogen heterogeneity in host tissues
As an additional complexity, pathogens show significantly increased single-cell heterogeneity in tissues and body fluids of human patients and infected animals, compared with homogeneous laboratory cultures3,44–46. This includes wide variation in bacterial growth rates, aggregation state, drug-efflux pumps, metabolism, and stress responses. All of these parameters influence the activity of antimicrobials, and it is possible that pathogen subsets with favorable properties tolerate antimicrobial exposure much better than their conspecifics, making eradication more difficult. Host-induced pathogen heterogeneity can reflect inhomogeneous host microenvironments triggering differences in bacterial physiology45–47 but also host-induced pathogen activities that change local microenvironments48.
An astonishing early finding was the differential recovery of Mycobacterium tuberculosis from open and closed (that is, no connection to airways) cavities in the lung of patients with tuberculosis49. Whereas drug-resistant M. tuberculosis recovered from open cavities formed visible colonies on plates within a few weeks, M. tuberculosis from closed cavities of the same patients appeared only after a lag of many months. Strikingly, these colonies showed full drug susceptibility, suggesting limited selection for resistance development despite extended antimicrobial treatment. Sputum of patients with tuberculosis also contains mycobacteria with a wide range of cultivation phenotypes50. A recent example that directly reveals heterogeneous bacteria physiology in tissues comes from Salmonella mouse infection models. Salmonella shows local and transient adaptations to divergent nutrient supply and disparate antimicrobial host attacks with reactive oxygen and nitrogen species51. The resulting heterogeneity in Salmonella growth rates has a major impact on Salmonella eradication52–54.
Drug concentration at the site of infection
Antimicrobials must reach bacterial cells to execute their bactericidal/bacteriostatic activities. Bacterial subsets hiding in tissue microenvironments with poor drug penetration might delay complete eradication during antimicrobial chemotherapy. Indeed, host anatomy and biochemistry might provide physical or chemical barriers (or both) for drug penetration. This includes the blood–brain barrier, bones, and serum proteins that bind antimicrobials, thereby decreasing their free concentration. Host inflammation increases tissue heterogeneity by altering endothelial permeability and the formation of lesions and abscesses. On the other hand, certain drugs such as fluoroquinolones, azithromycin, and bedaquiline accumulate in host phagocytes55–57, which might lead to elevated drug concentrations around the bacteria. Antimicrobial availability at the site of infection depends on the intestinal absorption of orally administered drugs, the distribution to the infected tissue, metabolism, and excretion. All of these processes depend on the physicochemical properties of the drug as well as the physiology of the patient, which might vary during bacterial infection. Drug penetration into accessible tissues can be measured by using microdialysis58, but analysis of body fluids such as serum, cerebrospinal fluid, tracheal secretions, or urine is more common. It is unclear how representative these values are for drug availability around the bacterial cells during infection. Indeed, novel methods such as matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging demonstrate remarkable differences in local drug concentrations in lesions compared with surrounding lung tissue in tuberculosis patients and animals infected with M. tuberculosis59,60. The emerging data suggest that inhomogeneous drug exposure could be a crucial factor for difficulties in eradicating M. tuberculosis. Unfortunately, experimental data are lacking for most other infectious diseases.
Conclusions
Antibiotic chemotherapy of most bacterial infections is highly effective if the causative pathogen is susceptible to the antibiotic of choice. However, some infections require extended treatments to prevent relapses. Antibiotic-tolerant bacterial subsets (“persisters”) as observed in laboratory cultures might contribute to this problem. Alternatively, the host tissue environment could be decisive by providing inhomogeneous stress conditions and limiting drug distribution. To clarify these issues, we need more integrated in vivo research exploiting recent single-cell approaches and complementary techniques such as mass spectrometry imaging and three-dimensional high-resolution whole-organ microscopy61,62. A better understanding of the real problems impairing the chemotherapy of such infections is critically important to devise novel strategies for more effective and rapid treatments.
Faculty Opinions recommended
References
1.
Dawson-Hahn EE, Mickan S, Onakpoya I, et al.:
Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: a review of systematic reviews.
Fam Pract.
2017; 34(5): 511–9. PubMed Abstract
| Publisher Full Text
| Free Full Text
2.
Hanretty AM, Gallagher JC:
Shortened Courses of Antibiotics for Bacterial Infections: A Systematic Review of Randomized Controlled Trials.
Pharmacotherapy.
2018; 38(6): 674–87. PubMed Abstract
| Publisher Full Text
3.
Davis KM, Isberg RR:
Defining heterogeneity within bacterial populations via single cell approaches.
Bioessays.
2016; 38(8): 782–90. PubMed Abstract
| Publisher Full Text
5.
Santi I, Dhar N, Bousbaine D, et al.:
Single-cell dynamics of the chromosome replication and cell division cycles in mycobacteria.
Nat Commun.
2013; 4: 2470. PubMed Abstract
| Publisher Full Text
6.
Balaban NQ, Helaine S, Lewis K, et al.:
Definitions and guidelines for research on antibiotic persistence.
Nat Rev Microbiol.
2019; 17(7): 441–8. PubMed Abstract
| Publisher Full Text
7.
Ryall B, Eydallin G, Ferenci T:
Culture history and population heterogeneity as determinants of bacterial adaptation: the adaptomics of a single environmental transition.
Microbiol Mol Biol Rev.
2012; 76(3): 597–625. PubMed Abstract
| Publisher Full Text
| Free Full Text
8.
Zalis EA, Nuxoll AS, Manuse S, et al.:
Stochastic Variation in Expression of the Tricarboxylic Acid Cycle Produces Persister Cells.
MBio.
2019; 10(5): pii: e01930-19. PubMed Abstract
| Publisher Full Text
| Free Full Text
9.
Vazquez-Laslop N, Lee H, Neyfakh AA:
Increased persistence in Escherichia coli caused by controlled expression of toxins or other unrelated proteins.
J Bacteriol.
2006; 188(10): 3494–7. PubMed Abstract
| Publisher Full Text
| Free Full Text
10.
Kwan BW, Valenta JA, Benedik MJ, et al.:
Arrested protein synthesis increases persister-like cell formation.
Antimicrob Agents Chemother.
2013; 57(3): 1468–73. PubMed Abstract
| Publisher Full Text
| Free Full Text
11.
Amato SM, Orman MA, Brynildsen MP:
Metabolic control of persister formation in Escherichia coli.
Mol Cell.
2013; 50(4): 475–87. PubMed Abstract
| Publisher Full Text
16.
Bhaskar A, De Piano C, Gelman E, et al.:
Elucidating the role of (p)ppGpp in mycobacterial persistence against antibiotics.
IUBMB Life.
2018; 70(9): 836–44. PubMed Abstract
| Publisher Full Text
17.
Goormaghtigh F, Van Melderen L:
Single-cell imaging and characterization of Escherichia coli persister cells to ofloxacin in exponential cultures.
Sci Adv.
2019; 5(6): eaav9462. PubMed Abstract
| Publisher Full Text
| Free Full Text
23.
Mulcahy LR, Burns JL, Lory S, et al.:
Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis.
J Bacteriol.
2010; 192(23): 6191–9. PubMed Abstract
| Publisher Full Text
| Free Full Text
24.
Schumacher MA, Balani P, Min J, et al.:
HipBA-promoter structures reveal the basis of heritable multidrug tolerance.
Nature.
2015; 524(7563): 59–64. PubMed Abstract
| Publisher Full Text
25.
Nemeth J, Oesch G, Kuster SP:
Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis.
J Antimicrob Chemother.
2015; 70(2): 382–95. PubMed Abstract
| Publisher Full Text
26.
Conlon BP, Rowe SE, Lewis K:
Persister cells in biofilm associated infections.
Adv Exp Med Biol.
2015; 831: 1–9. PubMed Abstract
| Publisher Full Text
36.
Stubbings W, Leow P, Yong GC, et al.:
In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.
Antimicrob Agents Chemother.
2011; 55(9): 4394–7. PubMed Abstract
| Publisher Full Text
| Free Full Text
38.
Sakoulas G, Kumaraswamy M, Kousha A:
Interaction of Antibiotics with Innate Host Defense Factors against Salmonella enterica Serotype Newport.
mSphere.
2017; 2(6): pii: e00410-17. PubMed Abstract
| Publisher Full Text
| Free Full Text
40.
Eng RH, Padberg FT, Smith SM, et al.:
Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria.
Antimicrob Agents Chemother.
1991; 35(9): 1824–8. PubMed Abstract
| Publisher Full Text
| Free Full Text
41.
Sufya N, Allison DG, Gilbert P:
Clonal variation in maximum specific growth rate and susceptibility towards antimicrobials.
J Appl Microbiol.
2003; 95(6): 1261–7. PubMed Abstract
| Publisher Full Text
42.
Smirnova GV, Oktyabrsky ON:
Relationship between Escherichia coli growth rate and bacterial susceptibility to ciprofloxacin.
FEMS Microbiol Lett.
2018; 365(1): fnx254. PubMed Abstract
| Publisher Full Text
47.
Mitchison DA:
The action of antituberculosis drugs in short-course chemotherapy.
Tubercle.
1985; 66(3): 219–25. PubMed Abstract
| Publisher Full Text
49.
Vandiviere HM, Loring WE, Melvin I, et al.:
The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection.
Am J Med Sci.
1956; 232(1): 30–7; passim. PubMed Abstract
| Publisher Full Text
50.
Chengalroyen MD, Beukes GM, Gordhan BG, et al.:
Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis.
Am J Respir Crit Care Med.
2016; 194(12): 1532–40. PubMed Abstract
| Publisher Full Text
| Free Full Text
51.
Burton NA, Schürmann N, Casse O, et al.:
Disparate impact of oxidative host defenses determines the fate of Salmonella during systemic infection in mice.
Cell Host Microbe.
2014; 15(1): 72–83. PubMed Abstract
| Publisher Full Text
53.
Kaiser P, Regoes RR, Dolowschiak T, et al.:
Cecum lymph node dendritic cells harbor slow-growing bacteria phenotypically tolerant to antibiotic treatment.
PLoS Biol.
2014; 12(2): e1001793. PubMed Abstract
| Publisher Full Text
| Free Full Text
54.
Claudi B, Spröte P, Chirkova A, et al.:
Phenotypic variation of Salmonella in host tissues delays eradication by antimicrobial chemotherapy.
Cell.
2014; 158(4): 722–33. PubMed Abstract
| Publisher Full Text
55.
Panteix G, Guillaumond B, Harf R, et al.:
In-vitro concentration of azithromycin in human phagocytic cells.
J Antimicrob Chemother.
1993; 31 Suppl E: 1–4. PubMed Abstract
| Publisher Full Text
56.
Vallet CM, Marquez B, Ngabirano E, et al.:
Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.
Int J Antimicrob Agents.
2011; 38(3): 249–56. PubMed Abstract
| Publisher Full Text
57.
Greenwood DJ, Dos Santos MS, Huang S, et al.:
Subcellular antibiotic visualization reveals a dynamic drug reservoir in infected macrophages.
Science.
2019; 364(6447): 1279–82. PubMed Abstract
| Publisher Full Text
58.
Marchand S, Chauzy A, Dahyot-Fizelier C, et al.:
Microdialysis as a way to measure antibiotics concentration in tissues.
Pharmacol Res.
2016; 111: 201–7. PubMed Abstract
| Publisher Full Text
59.
Prideaux B, Lenaerts A, Dartois V:
Imaging and spatially resolved quantification of drug distribution in tissues by mass spectrometry.
Curr Opin Chem Biol.
2018; 44: 93–100. PubMed Abstract
| Publisher Full Text
61.
Cronan MR, Rosenberg AF, Oehlers SH, et al.:
CLARITY and PACT-based imaging of adult zebrafish and mouse for whole-animal analysis of infections.
Dis Model Mech.
2015; 8(12): 1643–50. PubMed Abstract
| Publisher Full Text
| Free Full Text
This work was supported by Swiss National Foundation grants 310030_156818 and 310030_18231
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Bumann D, Fanous J, Li J and Goormaghtigh F. Antibiotic chemotherapy against heterogeneous pathogen populations in complex host tissues [version 1; peer review: 2 approved] F1000Research 2019, 8(F1000 Faculty Rev):1781 (https://doi.org/10.12688/f1000research.19441.1)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.
Share
Open Peer Review
Current Reviewer Status:
?
Key to Reviewer Statuses
VIEWHIDE
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations -
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Adjust parameters to alter display
View on desktop for interactive features
Includes Interactive Elements
View on desktop for interactive features
Competing Interests Policy
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Examples of 'Non-Financial Competing Interests'
Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.
You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).
You work at the same institute as any of the authors.
You hope/expect to benefit (e.g. favour or employment) as a result of your submission.
You are an Editor for the journal in which the article is published.
Examples of 'Financial Competing Interests'
You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.
You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.
You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.
Stay Updated
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Comments on this article Comments (0)